| 1 |
NCT02067052 |
Recruiting |
New Strategy for the Treatment of Vulvar Cancer |
|
- Procedure: Surgery, radiotherapy and chemotherapy
- Procedure: Surgery
|
Observational |
|
- Instituto do Cancer do Estado de São Paulo
- University of Sao Paulo General Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
|
21 |
Female |
18 Years and older (Adult, Senior) |
NCT02067052 |
NP 245/12 |
|
July 2012 |
October 2018 |
December 2018 |
February 20, 2014 |
January 17, 2018 |
|
- USPauloGH
São Paulo, Brazil
|
| 2 |
NCT02988765 |
Recruiting |
Ultrasound Morphometric and Cyto/Histological Combined Pre-operative Assessment of Inguinal Lymph Node Status in Women With Invasive Vulvar Carcinoma |
|
- Procedure: Groin ultrasound +/- fine needle aspiration
|
Interventional |
Not Applicable |
- Catholic University of the Sacred Heart
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Accuracy, negative predictive value (NPV) and positive predictive value (PPV) of ultrasound morphometry (USM) in the prediction of groin lymph node status
- Accuracy, negative predictive value (NPV) and positive predictive value (PPV) of fine needle aspiration in the prediction of groin lymph node status
|
120 |
Female |
18 Years and older (Adult, Senior) |
NCT02988765 |
Morpho-Node |
Morpho-Node |
December 2016 |
December 2018 |
December 2018 |
December 9, 2016 |
December 9, 2016 |
|
- Division of Gynecologic Oncology/Fondazione Policlinico Gemelli
Rome, Italy
|
| 3 |
NCT02969278 |
Recruiting |
Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy |
|
- Procedure: 18FDG-PET/TC
- Procedure: Sentinel node biopsy
|
Interventional |
Not Applicable |
- Catholic University of the Sacred Heart
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Accuracy and Negative Predictive Value of sentinel node biopsy in cN0 vulvar cancer patients that do not fit for the current indications
- Accuracy and Negative Predictive Value of preoperative 18F FDG-PET/CT for the selection of cN0 patients.
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT02969278 |
GroSNaPET |
GroSNaPET |
July 2013 |
July 2017 |
July 2017 |
November 21, 2016 |
November 21, 2016 |
|
- Division of Gynecologic Oncology/Fondazione Policlinico Gemelli
Rome, Italy
|
| 4 |
NCT03142061 |
Recruiting |
Electrochemotherapy for the Inoperable Vulva Carcinoma |
- Advanced Inoperable Vulva Carcinoma
|
- Procedure: Electrochemotherapy
|
Interventional |
Not Applicable |
- University Women's Hospital Tübingen
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- local tumor control
- Symptom control
- Life quality
- Pain
|
50 |
Female |
55 Years and older (Adult, Senior) |
NCT03142061 |
558/2015BO1 |
|
June 1, 2017 |
June 1, 2019 |
December 31, 2019 |
May 5, 2017 |
July 14, 2017 |
|
- Department of Women's Health
Tübingen, Germany
|
| 5 |
NCT01595061 |
Recruiting |
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva |
- Stage IIIA Vulvar Cancer AJCC v7
- Stage IIIB Vulvar Cancer AJCC v7
- Stage IIIC Vulvar Cancer AJCC v7
- (and 2 more...)
|
- Drug: Cisplatin
- Drug: Gemcitabine Hydrochloride
- Radiation: Intensity-Modulated Radiation Therapy
- Procedure: Therapeutic Conventional Surgery
|
Interventional |
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete pathologic response evaluated as the frequency of complete clinical and pathologic response after primary therapy
- Complete clinical response, defined as no clinical/radiographic evidence of primary disease (vulvar or groin) following chemo-radiation therapy
- Incidence and severity of adverse effects tabulated based on the Common Terminology Criterial for Adverse Events (CTCAE) v 4.0
- (and 4 more...)
|
52 |
Female |
18 Years and older (Adult, Senior) |
NCT01595061 |
GOG-0279
NCI-2012-01964
CDR0000732793
U10CA180868
U10CA027469 |
|
July 2, 2012 |
September 30, 2019 |
|
May 9, 2012 |
February 16, 2018 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 180 more...)
|
| 6 |
NCT03285841 |
Not yet recruiting |
OCT-AF Imaging of Pre-cancers of Vulva and Cervix |
- Cervical Dysplasia
- Vulvar Dysplasia
- Precancerous Lesions
- (and 2 more...)
|
|
Observational |
|
- British Columbia Cancer Agency
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Observational Model: Other
- Time Perspective: Other
|
- Determine ease of use of OCT-AFI in imaging cervix or vulva lesions.
- Correlate OCT-AFI images with histology images
- Quantify OCT-AFI images by examining epithelial thickness
- (and 2 more...)
|
20 |
Female |
18 Years and older (Adult, Senior) |
NCT03285841 |
BCCR-H17-02004 |
|
May 30, 2018 |
January 1, 2019 |
December 31, 2019 |
September 18, 2017 |
February 6, 2018 |
|
|
| 7 |
NCT03452332 |
Not yet recruiting |
Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Cervical, Vaginal, or Vulvar Cancer |
- Malignant Neoplasms of Female Genital Organs
- Cervical Cancer
- Vaginal Cancer
- Vulvar Cancer
|
- Drug: Durvalumab
- Drug: Tremelimumab
- Radiation: Stereotactic Ablative Radiotherapy (SABR)
|
Interventional |
Phase 1 |
- M.D. Anderson Cancer Center
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety Assessed Based on Dose Limiting Toxicities (DLTs) Based on Adverse Events (AEs) Assessed by NCI CTCAE v 4.03.)
- Clinical Response Rate Measured by Tumor Response Based on RECIST Criteria v 1.1
- Objective Response Defined as Complete Response (CR) or Partial Response (PR) by RECIST v1.1.
- (and 3 more...)
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT03452332 |
2017-0548 |
|
May 2018 |
October 2019 |
October 2020 |
March 2, 2018 |
April 18, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 8 |
NCT03061435 |
Not yet recruiting |
Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. |
- Vulvar Cancer
- Cervical Cancer
- Vulvar Dysplasia
- (and 4 more...)
|
- Procedure: Screening anal Pap smear - No high-resolution anoscopy
- Procedure: Screening anal Pap smear - High-resolution anoscopy
|
Interventional |
Not Applicable |
- Dr. Danielle Vicus
- Sunnybrook Health Sciences Centre
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Prevalence of abnormal anal cytology and hrHPV DNA in women with VIN 2/3 or vulvar cancer
- Prevalence of AIN in women with VIN 2/3 or vulvar cancer
- Assess t he correlation between abnormal anal cytology, hrHPV DNA, and AIN
|
110 |
Female |
40 Years and older (Adult, Senior) |
NCT03061435 |
GYNEOCC 3 |
Vulvar-AIN |
December 2017 |
December 2018 |
December 2018 |
February 23, 2017 |
October 4, 2017 |
|
|
| 9 |
NCT03082950 |
Recruiting |
HPV Infections, Cancer of the Vulva and Therapeutical Success |
|
- Diagnostic Test: polymerase chain reaction
|
Observational |
|
- University of Luebeck
- EUROIMMUN Medizinische Labordiagnostika AG
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- prevalence of hpv infections among pations suffering from vulvar cancer and preinvasive lesions
- disease free survival among the groups
|
100 |
Female |
Child, Adult, Senior |
NCT03082950 |
HL-15-220 |
|
October 2015 |
December 2017 |
December 2018 |
March 17, 2017 |
March 21, 2017 |
|
- Luebeck University, Department for obstetrics and gynecology
Luebeck, Schleswig Holstein, Germany
|
| 10 |
NCT03403465 |
Recruiting |
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers |
- Cancer of the Cervix
- Vulvar Cancer
- Esophageal Cancer
- Anal Canal Cancer
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The number of subjects with benefit from an intra-treatment PET-CT
- Pathologic complete response
- Locoregional control
- (and 4 more...)
|
130 |
All |
18 Years and older (Adult, Senior) |
NCT03403465 |
Pro00089619 |
|
March 27, 2018 |
February 2021 |
February 2021 |
January 18, 2018 |
April 17, 2018 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
| 11 |
NCT02981862 |
Recruiting |
CaptHPV : Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas |
- Cervical Cancer
- Vulvar Cancer
- Anal Cancer
- Oropharynx Cancer
|
|
Interventional |
Not Applicable |
- Institut de Cancérologie de Lorraine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Assessement of CaptHPV method
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02981862 |
2016-A01085-46 |
CaptHPV |
December 19, 2016 |
December 2018 |
December 2018 |
December 5, 2016 |
April 17, 2018 |
|
- Institut de Cancérologie de Lorraine
Vandoeuvre-lès-Nancy, France
|
| 12 |
NCT02412124 |
Recruiting |
Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers |
- Cervical Carcinoma
- Ovarian Carcinoma
- Uterine Corpus Cancer
- (and 2 more...)
|
- Procedure: Supportive Care
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
|
Interventional |
Not Applicable |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change in quality of life benefits for patients, as assessed by the FACT-G
- Satisfaction of patients with the timing, content, and format of the program, as assessed by the W2W Patient Survey
- Satisfaction of mentors with the timing, content, and format of the program, as assessed by the W2W Volunteer/Mentor Survey
- (and 2 more...)
|
30 |
Female |
19 Years and older (Adult, Senior) |
NCT02412124 |
14359
NCI-2015-00467 |
|
July 2015 |
July 2018 |
July 2018 |
April 8, 2015 |
February 19, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States
|
| 13 |
NCT02858310 |
Recruiting |
E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers |
- Papillomavirus Infections
- Cervical Intraepithelial Neoplasia
- Carcinoma In Situ
- (and 2 more...)
|
- Biological: E7 TCR Transduced PBL cells
- Drug: pembrolizumab
- Drug: aldesleukin
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine a safe dose for E7 TCR cells plus aldesleukin with or without pembrolizumab
|
180 |
All |
18 Years to 66 Years (Adult, Senior) |
NCT02858310 |
160154
16-C-0154 |
|
August 4, 2016 |
December 31, 2020 |
January 1, 2026 |
August 8, 2016 |
March 12, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 14 |
NCT02993900 |
Recruiting |
Image-Guided Gynecologic Brachytherapy |
- Cervical Cancer
- Uterine Cancer
- Vaginal Cancer
- (and 2 more...)
|
- Device: Image-Guided Brachytherapy
|
Interventional |
Phase 2 |
- Sidney Kimmel Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dosing changes
- The rate of treatment-related toxicity
- Time to local failure
- Rate of survival
|
54 |
Female |
18 Years to 100 Years (Adult, Senior) |
NCT02993900 |
J1660
IRB00098525 |
|
September 2016 |
September 2021 |
|
December 15, 2016 |
December 12, 2017 |
|
- The SKCCC at Johns Hopkins
Baltimore, Maryland, United States
|
| 15 |
NCT00791635 |
Recruiting |
Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy |
- Cervical Cancer
- Endometrial Cancer
- Vaginal Cancer
- (and 2 more...)
|
- Behavioral: Questionnaires
|
Observational |
|
- M.D. Anderson Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Types of Complications Experienced by Women Undergoing Pelvic Exenteration
- Number of complications experienced by women who undergo pelvic exenteration by vaginal and bladder reconstruction types
|
200 |
Female |
18 Years and older (Adult, Senior) |
NCT00791635 |
2008-0095 |
|
September 2008 |
September 2019 |
September 2020 |
November 14, 2008 |
March 1, 2018 |
|
- Memorial City
Houston, Texas, United States - St. Luke's Episcopal Hospital
Houston, Texas, United States - University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 16 |
NCT02379520 |
Recruiting |
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA |
- Human Papillomavirus-Related Carcinoma
- Human Papillomavirus Positive Oropharyngeal Carcinoma
- Human Papillomavirus Positive Cervical Carcinoma
- (and 3 more...)
|
- Genetic: HPV Specific T Cells
- Drug: Cytoxan
- Drug: Fludarabine
- Biological: Nivolumab
|
Interventional |
Phase 1 |
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- The Methodist Hospital System
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with dose limiting toxicity (DLT)
- Overall response rate
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT02379520 |
H-36021 HESTIA |
HESTIA |
September 2015 |
October 2018 |
October 2033 |
March 5, 2015 |
June 14, 2017 |
|
- Houston Methodist Hospital
Houston, Texas, United States
|
| 17 |
NCT03277482 |
Recruiting |
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer |
- Recurrent Gynecological Cancer
- Metastatic Cervical Cancer
- Metastatic Ovarian Cancer
- (and 8 more...)
|
- Drug: Durvalumab
- Drug: Tremelimumab
- Radiation: Radiation Therapy
|
Interventional |
Phase 1 |
- Dana-Farber Cancer Institute
- AstraZeneca
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Radiotherapy with durvalumab and tremelimumab
- Overall Response Rate
- Local Response Rate
- (and 5 more...)
|
32 |
Female |
18 Years and older (Adult, Senior) |
NCT03277482 |
17-382 |
|
February 6, 2018 |
January 1, 2020 |
November 1, 2020 |
September 11, 2017 |
April 11, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 18 |
NCT02578888 |
Recruiting |
Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies |
- Cervical Carcinoma
- Ovarian Carcinoma
- Primary Peritoneal Carcinoma
- (and 7 more...)
|
- Other: Palliative Therapy
- Other: Palliative Therapy + idiographic
|
Interventional |
Not Applicable |
- Albert Einstein College of Medicine, Inc.
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Measure increased utilization (move from 18% to over 50%) of palliative medicine and increased proportion of patients receiving services more then 30 days before death as compared to historical controls.
- Measured by differential in aggresive care at end-of-life from direct hospital costs in the last 6 months of life between patients that are randomized and refuse randomization.
- Evaluate costs related to procedures, laboratories, radiographic studies, intensive care admission, and blood transfusion to create a model of potential cost savings as generalized to patients with non-gynecologic cancers within the CMO.
- FAMCARE Survey will be administered, a 20 item scale measuring the degree to which family members are satisfied with the healthcare providers' behaviors. Comparison of family member scores between 2 arms, as well as at face value will be evaluated.
|
180 |
Female |
Child, Adult, Senior |
NCT02578888 |
2014-4421
NCI-2015-00729
P30CA013330 |
|
April 2015 |
April 2018 |
April 2019 |
October 19, 2015 |
October 19, 2015 |
|
- Albert Einstein College of Medicine
Bronx, New York, United States
|
| 19 |
NCT03339765 |
Recruiting |
Self-Advocacy Serious Game in Advanced Cancer |
- Ovarian Cancer Stage III
- Ovarian Cancer Stage IV
- Breast Cancer Stage IV
- (and 10 more...)
|
- Behavioral: Strong Together serious game
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Number of participants who engage in at least 8 out of the 12 serious game sessions
- Number of participants who find the intervention acceptable based on ratings of the Post Study System Usability Questionnaire and qualitative interviews.
- Change in patient self-advocacy as assessed by the Female Self-Advocacy in Cancer Survivorship Scale.
- (and 4 more...)
|
81 |
Female |
18 Years and older (Adult, Senior) |
NCT03339765 |
PRO17070414 |
|
March 9, 2018 |
April 30, 2022 |
December 31, 2023 |
November 13, 2017 |
April 9, 2018 |
|
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
|
| 20 |
NCT03000192 |
Recruiting |
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life |
- Breast Cancer Female
- Breast Neoplasm
- Non-Hodgkin's B-cell Lymphoma
- (and 15 more...)
|
|
Observational |
|
- University Hospital Southampton NHS Foundation Trust
- University of Southampton
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Quality of Life in Adult Cancer Survivors (QLACS)
|
3000 |
All |
16 Years and older (Child, Adult, Senior) |
NCT03000192 |
RHM CAN1199 |
|
August 2016 |
December 2020 |
December 2020 |
December 21, 2016 |
April 11, 2018 |
|
- Bronglais General Hospital
Aberystwyth, United Kingdom - Antrim Hospital
Antrim, United Kingdom - William Harvey Hospital
Ashford, United Kingdom - (and 84 more...)
|
| 21 |
NCT02714621 |
Recruiting |
MR-HIFU for Recurrent Gynaecological Cancer |
- Cervical Cancer
- Endometrial Cancer
- Uterine Cancer
- (and 3 more...)
|
- Device: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
|
Interventional |
Not Applicable |
- Institute of Cancer Research, United Kingdom
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in pain, measured using a patient diary
- Changes in bleeding, measured using a questionnaire
|
35 |
Female |
18 Years and older (Adult, Senior) |
NCT02714621 |
15/WM/0470 CCR4360 |
HIFU-Gynae |
May 2016 |
May 2019 |
May 2019 |
March 21, 2016 |
January 12, 2017 |
|
- The Royal Marsden NHS Foundation Trust
Surrey, United Kingdom
|
| 22 |
NCT03220009 |
Not yet recruiting |
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma |
- Cervical Carcinoma
- Esophageal Carcinoma
- Mucosal Melanoma
- (and 14 more...)
|
- Procedure: Conventional Surgery
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrence free survival (RFS)
- Distant recurrence-free survival (DRFS)
- Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03220009 |
NCI-2017-01239
A091603
U10CA180821 |
|
November 3, 2017 |
July 1, 2021 |
July 1, 2021 |
July 18, 2017 |
October 17, 2017 |
|
- Alliance for Clinical Trials in Oncology
Boston, Massachusetts, United States
|
| 23 |
NCT00394602 |
Recruiting |
Chemoradiation-Induced Nausea and Emesis: Quality of Life |
- Gastric Cancer
- Pancreatic Cancer
- Cervical Cancer
- (and 3 more...)
|
- Behavioral: Interview
- Other: Questionnaire
|
Observational |
|
- M.D. Anderson Cancer Center
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Longitudinal Quality of Life + Symptom Assessment Data
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT00394602 |
2003-0529 |
|
April 2004 |
April 2019 |
April 2019 |
November 1, 2006 |
January 16, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 24 |
NCT03180294 |
Recruiting |
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer |
- Breast Carcinoma
- Cervical Carcinoma
- Ovarian Carcinoma
- (and 4 more...)
|
- Drug: Bupropion Hydrochloride
- Other: Placebo
|
Interventional |
Phase 2 |
- NRG Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Change in sexual desire, as measured by the desire subscale of the female sexual function index
- Depressive mood as measured by the patient health questionnaire-4
- Fatigue as measured by Patient Reported Outcomes Measurement Information System fatigue scale
- (and 3 more...)
|
234 |
Female |
18 Years and older (Adult, Senior) |
NCT03180294 |
NRG-CC004
NCI-2017-00344
UG1CA189867 |
|
May 31, 2017 |
October 30, 2019 |
May 31, 2027 |
June 8, 2017 |
January 9, 2018 |
|
- NRG Oncology
Philadelphia, Pennsylvania, United States
|
| 25 |
NCT01764802 |
Recruiting |
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer |
- Ovarian Sarcoma
- Ovarian Stromal Cancer
- Stage I Uterine Sarcoma
- (and 59 more...)
|
- Other: behavioral, psychological or informational intervention
|
Interventional |
Phase 2 |
- Ohio State University Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Sexual behavior/repertoire (kissing, intercourse, etc.) graded using the Sexual Experiences Scale (SES)
- Sexual responsiveness (desire, arousal, orgasm) using the Female Sexual Functioning Index (FSFI)
- Sexual satisfaction graded using the global evaluation from the Derogatis Sexual Function Inventory (DSFI)
- (and 7 more...)
|
100 |
Female |
21 Years to 80 Years (Adult, Senior) |
NCT01764802 |
OSU-10077
NCI-2012-01341
1R21CA149675-01A1 |
|
October 2010 |
August 2018 |
|
January 10, 2013 |
April 13, 2017 |
|
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, United States
|
| 26 |
NCT02786524 |
Recruiting |
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy |
- Uterine Cervical Neoplasms
- Ovarian Neoplasms
- Gynecologic Neoplasms
- (and 4 more...)
|
- Behavioral: Specialized Symptom Management and Supportive Care
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change in Patient-Reported Symptom Burden as Determined by the Edmonton Symptom Assessment System
- Change in Patient-Reported Symptom Burden as Determined by the National Comprehensive Cancer Network Distress Screening Tool
- Baseline Symptom Burden and Palliative Care Needs
- (and 5 more...)
|
180 |
Female |
18 Years and older (Adult, Senior) |
NCT02786524 |
HUM00089412 |
|
February 2016 |
February 2020 |
February 2020 |
June 1, 2016 |
March 20, 2018 |
|
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
|
| 27 |
NCT00005095 |
Recruiting |
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention |
- Cervical Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- (and 6 more...)
|
- Other: laboratory biomarker analysis
- Other: screening questionnaire administration
- Procedure: study of high risk factors
|
Observational |
|
- Northwestern University
- National Cancer Institute (NCI)
|
Other / NIH |
- Time Perspective: Prospective
|
- Identification and development of highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecological malignancies
- Identification of new prevention approaches and therapies
- Identification of measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer
|
6000 |
Female |
18 Years to 80 Years (Adult, Senior) |
NCT00005095 |
NU 99G8
P30CA060553
NU-99G8
NCI-G00-1753 |
|
March 2000 |
December 2020 |
|
January 27, 2003 |
September 30, 2016 |
|
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States
|
| 28 |
NCT03372720 |
Recruiting |
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors |
- Cervical Carcinoma
- Dyspareunia
- Endometrial Carcinoma
- (and 4 more...)
|
- Procedure: Laser Therapy
- Other: Questionnaire Administration
- Procedure: Sham Intervention
|
Interventional |
Not Applicable |
- Ohio State University Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Change in genitourinary syndrome of menopause (GSM) symptoms
- Feasibility as measured by number of patients able to complete 3 study visitis
- Improvement in objective findings of vaginal atrophy
- (and 6 more...)
|
40 |
Female |
Child, Adult, Senior |
NCT03372720 |
OSU-17261
NCI-2017-02051
P30CA016058 |
|
March 28, 2018 |
December 31, 2020 |
December 31, 2020 |
December 14, 2017 |
April 5, 2018 |
|
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
| 29 |
NCT03346915 |
Not yet recruiting |
Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention |
- Human Papilloma Virus
- Cervical Cancer
- Human Papillomavirus Infection
- (and 5 more...)
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- HPV vaccine series start and completion
- HPV and Cervical Cancer awareness and knowledge
- Provider-patient communication about HPV vaccine and cervical cancer
- Wheel of Wellness (WoW) feasibility
|
30 |
All |
9 Years to 65 Years (Child, Adult) |
NCT03346915 |
H-36669 |
|
April 2018 |
December 2018 |
February 2019 |
November 20, 2017 |
March 6, 2018 |
|
|
| 30 |
NCT02997553 |
Recruiting |
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery |
- Breast Carcinoma
- Head and Neck Cancer
- Melanoma (Skin)
- (and 7 more...)
|
- Drug: Indocyanine green
- Drug: Technetium99
- Device: Optonuclear probe
|
Interventional |
Phase 3 |
- Institut de Cancérologie de Lorraine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Non-inferiority of indocyanine green guided sentinel lymph node biopsy
- Total number of sentinel lymph node detected
- Number of false negative result
- (and 2 more...)
|
744 |
All |
18 Years and older (Adult, Senior) |
NCT02997553 |
2016-A00799-42 |
GASVERT |
November 29, 2017 |
November 2020 |
November 2021 |
December 20, 2016 |
April 17, 2018 |
|
- Institut de Cancérologie de Lorraine
Vandoeuvre-les-Nancy, France
|
| 31 |
NCT02834013 |
Recruiting |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
- Acinar Cell Carcinoma
- Adenoid Cystic Carcinoma
- Adrenal Cortex Carcinoma
- (and 82 more...)
|
- Procedure: Biospecimen Collection
- Biological: Ipilimumab
- Biological: Nivolumab
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) defined as confirmed and unconfirmed complete and partial response
- Incidence of adverse events graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives
- (and 3 more...)
|
707 |
All |
18 Years and older (Adult, Senior) |
NCT02834013 |
NCI-2016-01041
S1609
U10CA180888 |
|
January 13, 2017 |
August 31, 2020 |
|
July 15, 2016 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 815 more...)
|
| 32 |
NCT02628067 |
Recruiting |
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) |
|
- Biological: pembrolizumab
|
Interventional |
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
|
1350 |
All |
18 Years and older (Adult, Senior) |
NCT02628067 |
3475-158
2015-002067-41
163196 |
|
December 18, 2015 |
August 28, 2023 |
August 28, 2023 |
December 11, 2015 |
February 7, 2018 |
|
- Call for Information (Investigational Site 0018)
Duarte, California, United States - Call for Information (Investigational Site 0202)
Los Angeles, California, United States - Call for Information (Investigational Site 0006)
San Francisco, California, United States - (and 35 more...)
|
| 33 |
NCT02140021 |
Recruiting |
Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer |
- Malignant Female Reproductive System Neoplasm
|
- Procedure: Anal Pap Test
- Procedure: Anoscopy
|
Interventional |
Not Applicable |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Prevalence of Invasive Squamous Cell Carcinoma of the Anus in Women with Cervical, Vaginal and Vulvar Dysplasia and Cancer
|
500 |
Female |
18 Years and older (Adult, Senior) |
NCT02140021 |
2014-0021 |
|
October 2014 |
October 2020 |
October 2020 |
May 16, 2014 |
August 17, 2017 |
|
- Lyndon B. Johnson General Hospital
Houston, Texas, United States - University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
Create an RSS feed from your search for:
Download the search results for: